Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human…
By E. Tan-chiu, G. Yothers, E. Romond, C. Geyer, M. Ewer, D. Keefe, R. Shannon, S. Swain, Ann M. Brown, L. Fehrenbacher and 6 more. Journal of Clinical Oncology, 2005
795 citations recorded by the source corpus.
Subfields: Cancer Research, Cardiology and Cardiovascular Medicine, Oncology
View Paper: https://www.semanticscholar.org/paper/db03abf49a364e4bf004350a66b9ca37d9fc6af9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- Gregory Y. H. Lip
- Jeroen J. Bax
- Helmut Baumgartner
- Paulus Kirchhof
- Jose Luis Zamorano
- D. Lenihan
- P. Lancellotti
- Stephan Windecker
Citations in the corpus
- Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. (2014, background): “Cumulative incidences of cardiac events peaked at 1 year after anthracycline treatment (11,12).”
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). (2016, background): “Thus it is recommended to administer anthracyclines before paclitaxel, separate the infusions and/or limit the cumulative doxorubicin dose to 360 mg/m(2).(277) As indicated above, the role of cardiac medications (ACE inhibitors, ARBs and beta-blockers) for the prevention of anthracyclineassociated c”
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (2016, background): “Thus it is recommended to administer anthracyclines before paclitaxel, separate the infusions and/or limit the cumulative doxorubicin dose to 360 mg/m(2).(277) As indicated above, the role of cardiac medications (ACE inhibitors, ARBs and beta-blockers) for the prevention of anthracyclineassociated c”